GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States.
Excellent balance sheet and fair value.
Share Price & News
How has GlycoMimetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GKO's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GKO underperformed the German Biotechs industry which returned 5.5% over the past year.
Return vs Market: GKO underperformed the German Market which returned 8.3% over the past year.
Price Volatility Vs. Market
How volatile is GlycoMimetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is GlycoMimetics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GKO (€3.56) is trading below our estimate of fair value (€23.12)
Significantly Below Fair Value: GKO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GKO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: GKO is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GKO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GKO is good value based on its PB Ratio (1x) compared to the DE Biotechs industry average (3.5x).
How is GlycoMimetics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GKO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GKO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GKO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if GKO's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if GKO's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GKO's Return on Equity is forecast to be high in 3 years time
How has GlycoMimetics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GKO is currently unprofitable.
Growing Profit Margin: GKO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GKO is unprofitable, and losses have increased over the past 5 years at a rate of -32.3% per year.
Accelerating Growth: Unable to compare GKO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GKO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: GKO has a negative Return on Equity (-34.16%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is GlycoMimetics's financial position?
Financial Position Analysis
Short Term Liabilities: GKO's short term assets ($174.8M) exceed its short term liabilities ($10.4M).
Long Term Liabilities: GKO's short term assets ($174.8M) exceed its long term liabilities ($2.9M).
Debt to Equity History and Analysis
Debt Level: GKO is debt free.
Reducing Debt: GKO had no debt 5 years ago.
Inventory Level: GKO has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if GKO's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GKO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if GKO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is GlycoMimetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate GKO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate GKO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GKO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GKO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GKO's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rachel King (60yo)
Mrs. Rachel K. King co-founded Glycomimetics, Inc. in 2003 and has been its Chief Executive Officer and its President since 2003. She has been a Director of Novavax, Inc. since November 1, 2018. Mrs. King ...
CEO Compensation Analysis
Compensation vs Market: Rachel's total compensation ($USD3.19M) is above average for companies of similar size in the German market ($USD626.29K).
Compensation vs Earnings: Rachel's compensation has increased whilst the company is unprofitable.
|Senior VP||8.1yrs||US$1.40m||no data|
|Senior VP of Research & Chief Scientific Officer||17.1yrs||US$1.56m||0.68% $1.1m|
|Senior VP of Clinical Development & Chief Medical Officer||14.1yrs||US$1.60m||0.34% $542.3k|
|Vice President of Accounting||1.1yrs||no data||no data|
|Vice President of Technical Operations||3.6yrs||no data||no data|
|VP, Corporate Counsel & Corporate Secretary||0.8yrs||no data||no data|
|Senior Vice President of Strategy and Corporate Development||5.8yrs||no data||no data|
Experienced Management: GKO's management team is seasoned and experienced (7 years average tenure).
|Senior VP of Research & Chief Scientific Officer||17.1yrs||US$1.56m||0.68% $1.1m|
|Independent Director||3.9yrs||US$192.43k||0.042% $65.7k|
|Chairman of the Board||0.8yrs||US$196.36k||no data|
|Independent Director||2.9yrs||US$180.29k||no data|
|Independent Director||2.7yrs||US$183.79k||no data|
|Independent Director||5.6yrs||US$189.79k||0.027% $42.0k|
Experienced Board: GKO's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.4%.
GlycoMimetics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: GlycoMimetics, Inc.
- Ticker: GKO
- Exchange: DB
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$172.139m
- Listing Market Cap: US$158.230m
- Shares outstanding: 43.36m
- Website: https://www.glycomimetics.com
Number of Employees
- GlycoMimetics, Inc.
- 9708 Medical Center Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GLYC||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jan 2014|
|GKO||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 2014|
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company’s advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/25 22:32|
|End of Day Share Price||2020/02/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.